Becky is Alchemab’s Human Resources Director where she oversees all strategic and operational HR activity across the U.K. and U.S. Prior to Alchemab, Becky served as the European HR Director at Silence Therapeutics, where she managed all aspects of human resources for the U.K. and German entities. Prior to joining Silence Therapeutics, Becky held various […]

Jenny Howell oversees project management at Alchemab and is responsible for managing our research and development portfolio and projects. Prior to joining Alchemab, Jenny held strategic portfolio and project management roles at AstraZeneca, MedImmune, Alizyme Therapeutics and GSK.   Jenny earned a BSc in applied Chemistry from Northumbria University.

Martin Butler is our Head of Operations where he oversees Alchemab’s site and scientific operations, procurement, and supply chain functions. Prior to joining Alchemab, Martin was Global Supply Chain Director for Horizon Discovery where he managed operational activities at sites within the UK and USA and led the organization’s response to Brexit and the recent […]

Donna Finch is Alchemab’s Head of Translational and Clinical Science where she oversees our target discovery and validation activities and our non-clinical and early clinical development efforts. Prior to joining Alchemab, Donna was Associate Director, Respiratory Inflammation and Autoimmunity, R&D Biopharmaceuticals at MedImmune and AstraZeneca, leading pre-clinical biology, translational and early clinical activities of several projects […]

Jake Galson is Alchemab’s Vice President of Technology where he leads the development and application of novel technologies for the company.  Prior to Alchemab, Jake was the Bioinformatics lead at Kymab Ltd, where his group developed the IntelliSelect® antibody discovery software platform. Jake is also one of the pioneers of immune receptor repertoire sequencing, serving […]